{"analyses":[{"ciLowerLimit":"0.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.56","estimateComment":"PD-L1 positive group","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Unstratified Hazard Ratio","paramValue":"0.37"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.80","estimateComment":"PD-L1 negative group","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Unstratified Hazard Ratio","paramValue":"0.60"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"31.47","upperLimit":"NA","value":"53.36"},{"groupId":"OG001","lowerLimit":"9.33","upperLimit":"18.99","value":"12.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"PD-L1 positive participants (cutoff=5%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.36","upperLimit":"39.79","value":"26.97"},{"groupId":"OG001","lowerLimit":"8.38","upperLimit":"12.25","value":"10.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"PD-L1 negative/indeterminate participants (cutoff=5%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"Overall Survival is defined as the time between the date of randomization and the date of death or the last date the participant was known to be alive. PD-L1 expression level is defined as the percent of tumor cells demonstrating plasma membrane PD-L1-staining in a minimum of 100 evaluable tumor cells per a Dako PD-L1 IHC (immunohistochemistry) assay (referred to as quantifiable PD-L1 expression). Assessment of OS by PD-L1 expression as measured by a validated assay and comparing OS in patients with tumor PD-L1 expression ≥5% (PD-L1 positive) versus patients with tumor PD-L1 expression \\<5% (PD-L1 negative). Tumor tissue samples for PD-L1 testing were collected at screening from metastatic or unresectable sites prior to randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG000","title":"Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine"},{"description":"Participants received dacarbazine 1000 mg/m\\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG001","title":"Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of disease progression or death, up to approximately 94 months","title":"Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level","type":"SECONDARY","unitOfMeasure":"Months"}